How many patents does
Amgen have?
patents
10,099
families
1,019
granted
2,386
applications
7,713
US
1,940
EP
1,107
WO
680
JP
540
CN
311
KR
256
GB
1
RoW
5,264
Buy the report
The report contains ten-year analysis with the following sections
- patent filing analysis
- worldwide filing analysis
- patent family analysis
- application analysis
- granted analysis
- classification analysis
- citation analysis
contact us for pricing
- VAT will apply to UK companies
- EU companies must supply their VAT number
Check out our sample pages |
Find companies to compare
Many companies now available
companies
12,000+
patents
42 million
patent families
23 million
Search to find companies of interest
read summary of their published patent
the following tables are just extracts from the report
the company report contains more information
Amgen
Top ten assignees appearing on patents
2009 - 2018
| amgen | 8352 |
| amgen fremont | 232 |
| medarex | 180 |
| amgen research (munich) | 156 |
| kirin-amgen | 123 |
| pfizer | 115 |
| u3 pharma | 112 |
| cytokinetics | 75 |
| ucb pharma | 55 |
| boehringer ingelheim international | 49 |
2009
| amgen | 789 |
| amgen fremont | 17 |
| medarex | 11 |
| pfizer | 10 |
| biovitrum | 7 |
| biovex | 7 |
| epix pharmaceuticals | 6 |
| u3 pharma | 6 |
| cytokinetics | 5 |
| alantos pharmaceuticals holding | 5 |
2018
| amgen | 723 |
| amgen research (munich) | 37 |
| amgen fremont | 25 |
| kirin-amgen | 19 |
| daiichi sankyo europe | 16 |
| pfizer | 13 |
| cytokinetics | 11 |
| medimmune | 11 |
| novo nordisk | 11 |
| teijin pharma | 10 |
Amgen
The top ten patent families are
|
Title of patent family (most common patent title) |
Family members |
Filing year |
|---|---|---|
| antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9) | 124 | 2007 |
| sclerostin binding agents | 121 | 2005 |
| il-17 receptor a antigen binding proteins | 80 | 2006 |
| human monoclonal antibodies to activin receptor-like kinase-1 | 74 | 2005 |
| piperidinone derivatives as mdm2 inhibitors for the treatment of cancer | 73 | 2010 |
| human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors | 69 | 2003 |
| variant activin receptor polypeptides and uses thereof | 67 | 2007 |
| alpha-4-beta-7 heterodimer specific antagonist antibody | 66 | 2009 |
| variants of activin iib receptor polypeptides and uses thereof | 64 | 2008 |
| therapeutic human anti-il-1r1 monoclonal antibody | 64 | 2002 |